Breast Cancer Female Clinical Trial
Official title:
Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn
Background: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug that has been
shown to reduce breakthrough narcotic consumption following orthopaedic, neurosurgical, and
obstetrical procedures. The morphine-sparing effect of ketorolac may reduce respiratory and
central nervous system depression post operatively, while still providing adequate pain
control for patients. Patients undergoing abdominally based microsurgical breast
reconstruction may particularly benefit from ketorolac postoperatively, and ultimately be
safely discharged from hospital sooner than their counterparts receiving standard of care.
Research Question: In adult women post-mastectomy, undergoing abdominally based microsurgical
breast reconstruction, does a postoperative regimen of intravenous ketorolac tromethamine, in
addition to standard of care, reduce the length of postoperative hospital stay compared with
an intravenous sham saline regimen?
Study Design: A single center, explanatory, placebo-controlled, 1:1 allocation, 2-arm,
parallel group, superiority, randomized, and double blinded, controlled trial.
Population: The study population includes all females >18 years old post mastectomy
consenting to abdominally based microsurgical breast reconstruction.
Intervention and Comparator: The intervention will be ketorolac 30 mg IV every 6 hours
postoperatively for 72 hours. The comparator will be a sham intravenous administration of
normal saline.
Outcomes: The primary outcome is hospital length of stay postoperatively. Secondary outcomes
include visual analog scale for pain, breakthrough narcotic consumption, surgical drain
outputs, hematoma, and other complications.
Sample Size: Available data provided estimates for average length of hospital stay and
standard deviation. A minimally clinically significant difference of 1 day was decided on due
to expert opinion. Based on a power of 80% and alpha of 0.05, and inflated to account for
attrition and efficiency losses, a total of 50 patients (25 per group) will be required for
this study.
Breast reconstruction (BR) is commonly requested following mastectomy, and recent measures
have been taken to ensure patient access is universal. Transferring autologous tissue from
the abdomen using microvascular surgical techniques provides a reliable reconstruction method
with high levels of patient satisfaction, and is routinely performed. However, the surgery is
relatively complex and lengthy; operative times can exceed six hours and hospital stay ranges
from 5-9 days. During each patient's postoperative course she must meet certain milestones
before discharge. It has been shown that beyond the necessary monitoring of the viability of
the free flap, pain and a patient's ability to mobilize are important modifiable barriers to
discharge.
Pain control following autologous BR is multimodal, but predominantly relies on opioids.
Narcotics provide effective analgesia, but have a well-known side effect profile that
includes drowsiness, nausea, vomiting, sedation, central nervous system and respiratory
depression. Each of these potential adverse effects limits patients' mobility after surgery.
Respiratory depression is particularly disadvantageous, as these patients have undergone
major abdominal musculature dissection that also disrupts their mechanics of breathing 10 .
This may have the counterproductive effect of limiting patient mobilization, and ultimately
delay discharge. In a health care system where resources are at a premium and costs are
climbing, any inexpensive intervention that allows for an earlier and safe discharge is
worthy of consideration.
No standard approach to postoperative pain control in free flap BR exists. Most protocols are
institution dependent, and variably incorporate narcotics, nonsteroidal anti-inflammatory
drugs (NSAIDs), acetaminophen and other agents. In addition, these medications are given via
oral, intramuscular, or intravenous routes. Recent studies have investigated the use of
transversus abdominis plane blocks as an analgesic adjunct, and patients are often provided
with patient-controlled analgesia (PCA) pumps in the early postoperative period.
Ketorolac tromethamine is an NSAID, which is approved by Health Canada for short-term pain
control (Toradol, Hoffmann-La Roche Limited, 7070 Mississauga Road Mississauga, Ontario).
Ketorolac provides better pain control than the most commonly used NSAIDs, and its potency is
comparable to that of morphine. However, it does not have the same listed side effects of
drowsiness and respiratory depression as do narcotics. Surgeons often cite concern regarding
postoperative bleeding when using NSAIDs, however recent reviews have convincingly
demonstrated the safety for use of NSAIDs in plastic surgery. A previous observational study
has also shown the safety of ketorolac specifically following autologous BR. The routine
addition of ketorolac following surgery has been shown to reduce patients' narcotic
requirements in other fields of surgery, such as orthopaedics and gynaecology.
Given the abovementioned advantages of ketorolac, and the particular propensity for
abdominally based free flap BR patients to be negatively affected by narcotic side effects,
we hypothesize that the addition of ketorolac to a routine multimodal postoperative analgesia
regimen will reduce hospital stay by a day or more.
The comparator for this study will be a placebo. Patients randomized both to the control
group and those randomized to the intervention group will receive standard of care
postoperatively, which will include pain control with scheduled acetaminophen and pro re nata
oral and subcutaneous hydromorphone. In addition, control patients will receive a placebo
with the same scheduling as the study drug, ketorolac. The rationale for this choice is to
limit potential sources of bias, such as the patient and her care team, and maximize the
accuracy of the primary outcome and patient-completed questionnaires that will serve as a
secondary outcome. Other authors have previously successfully used placebos for ketorolac in
their study design.
The majority of surgeons at our institution currently do not employ ketorolac in their
postoperative pain control regimen. Thus, there exists clinical equipoise for patients
considering participating and potentially being randomized into the control group, when
compared with declining participation and receiving usual care.
This study will be single-centered and conducted in Nova Scotia, Canada. The Halifax
Infirmary is a level III trauma center with multiple board certified Plastic surgeons who
have undertaken extra training in microsurgery.
Participants will be removed from the study upon request. Her data up until that point will
be used for statistical analysis, however she would no longer receive the intervention.
Modifications to intervention dosing would occur if a participant develops any drug
hypersensitivity reaction. Additionally any major harm attributed to ketorolac will prompt a
termination of the intervention.
Each patient will undergo uni- or bilateral abdominally based free flap harvest,
microsurgical anastomoses, and flap inset. Following randomization, the study drug will be
sent to the main operating theatre, and attached to the patient's medical chart. At the
conclusion of surgery, each patient will be administered their first dose of the study drug.
Its content will depend on the patient's randomized group. If randomized to the ketorolac
intervention group, the IV minibag will contain 30 mg of ketorolac tromethamine, or if in the
control group it will be a sham normal saline IV minibag. They then will continue to receive
their assigned drug every 6 hours for 72 hours. Patients all receive 1:1 care from nursing
staff in the early postoperative period, and their nurse will administer all drugs given on
the surgical ward.
All patients who have enrolled will receive the usual care for the postoperative period. The
study drug will be in addition to usual flap monitoring, patient vital sign monitoring,
progression of mobilization, drain management, along with the other care provided for these
patients. Patients also will have the same background analgesic and anti-emetics medications
ordered postoperatively, which is included on a standardized pre-printed order form at the
Halifax Infirmary for this particular surgery.
Potential participants will first be introduced to the study following their initial
consultation for BR. If the patient consents for abdominally based microsurgical BR, then the
study will be reviewed, allowing time for any questions to be asked, and the risks and
benefits to be discussed. The patient will be sent home with a study package that includes a
copy of the study consent form and protocol. The study will be reviewed again at a
preoperative appointment, allowing time for any follow up questions to be asked. This is a
routine appointment intended for markings and patient questions regarding surgery, and the
patient will officially be enrolled in the study if she wishes to participate at either
time-point - the initial consultation or the preoperative appointment. Following the surgery,
each patient will remain active in the study until her discharge from hospital. No follow up
appointments or data will be scheduled or recorded for the purposes of the study (although
follow up will occur as per usual with these patients and their respective surgeon).
Therefore total enrolment time for each patient will be from the appointment immediately
before surgery to her discharge from hospital.
A computer-generated algorithm will be used to randomize patients in a 1:1 allocation into
the intervention or control group during surgery. Randomization will be stratified by
laterality of the reconstruction (i.e. bi- or unilateral) because this could affect
participant pain levels. Randomization will be managed and maintained by a third party
service, not otherwise involved in the study, in the hospital pharmacy department. Allocation
methods will not be disclosed to study investigators. Following randomization, the study drug
will be sent to the main operating theatre, and given at the conclusion of the surgery. Both
the intervention and control drug will be of the same storage and opacity to prevent
identification by the patient or care providers. From there, the patient will then be
administered the same drug according to the randomization result, based on delivery by the
third party pharmacy service.
Randomization will be carried out within the pharmacy department placing patients into either
the intervention or control group. The intervention and control intravenous drugs will be
prepared in the same style IV minibag with the same volume and opacity of fluid. The fluids
will be of similar viscosity. Once similar appearances and features are confirmed the
prepared drug will be sent to the operating theatre or the ward as required depending on the
time point.
During the conduction of this study all involved trial participants, clinicians, data
collectors, event adjudicators, and data analysts will be blinded to the grouping of
patients. All study medications will be stored in the hospital pharmacy department by a third
party. Following randomization, treatment drugs will be dispensed by the pharmacy and then
administered by nursing staff. The third party service will maintain records linking a
patient unique identifier to her study group. Post hoc analysis to assess whether staff could
identify between the intervention and placebo will be conducted.
Harms will be classified as either minor or major. Minor harms will include surgical site
infection and those listed from prior clinical trials on the drug monograph, namely:
Common Clinical Trial Adverse Drug Reactions (>1%): Dyspepsia, abdominal pain, nausea,
constipation, diarrhea, flatulence, gastrointestinal fullness, peptic ulcers, headache,
dizziness, somnolence, edema
Less Common Clinical Trial Adverse Drug Reactions (≤ 1%): Eructation, stomatitis, vomiting,
anorexia, duodenal ulcer, gastritis, increased appetite, melena, mouth ulceration, rectal
bleeding, sore mouth, abnormal dreams, anxiety, depression, dry mouth, insomnia, nervousness,
paresthesia, tinnitus, taste perversion, abnormal vision, blurred vision, deafness,
lacrimation disorder, weight gain, alkaline phosphatase increase, BUN increased, excessive
thirst, generalized edema, hyperuricemia, pruritus, rash, burning sensation, asthenia, pain,
back pain, face edema, hernia, arthralgia, myalgia, joint disorder, chest pain, chest pain
substernal, migraine, dyspnea, asthma, epistaxis, hematuria, increased urinary frequency,
oliguria, polyuria, anemia, purpura
No major harms are anticipated. Major harms will include but are not limited to (* indicates
possible association with oral ketorolac from drug monograph, <1%):
Surgical site hemorrhage requiring re-exploration in the main operating theatre
Gastrointestinal hemorrhage* Pulmonary embolus Death
Any harm identified by care providers during enrolment of the study will be communicated to
the principal and sub investigators. Minor harms will be communicated within 5 days. Any
major harm will be communicated to the research ethics board within 24 hours. Complications
will be managed medically in standard fashion, and the research will have no bearing on
patient care. Emergency unblinding will be available to the patients' care providers at all
times, as above.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03080623 -
Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
|
||
Completed |
NCT05527769 -
Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
|
||
Completed |
NCT03004534 -
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
|
Early Phase 1 | |
Recruiting |
NCT05020574 -
Microbiome and Association With Implant Infections
|
Phase 2 | |
Active, not recruiting |
NCT06277141 -
The Vitality Mammography Messaging Study
|
N/A | |
Completed |
NCT03270111 -
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
|
N/A | |
Completed |
NCT03555227 -
USG PECS vs LIA for Breast Cancer Surgery
|
N/A | |
Active, not recruiting |
NCT03917082 -
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05561842 -
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
|
||
Completed |
NCT04554056 -
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06351332 -
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03127995 -
Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence
|
N/A | |
Active, not recruiting |
NCT02237469 -
Prone Breast Radiotherapy Treatment Planning Observational Study
|
||
Completed |
NCT01204125 -
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04565054 -
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
|
Phase 3 | |
Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
Recruiting |
NCT06087120 -
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
|
||
Recruiting |
NCT06058936 -
Exercises Using Virtual Reality on Cancer Patients
|
N/A | |
Completed |
NCT03470935 -
Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger
|
||
Recruiting |
NCT06025604 -
ACTIVPROSEIN : Professional Activity After Breast Cancer
|